ReviewJournal of the Endocrine Society2018
Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease.
Review in Journal of the Endocrine Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 46 citations in OpenAlex.
- Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation.Bone research · 2026Review
- Identification and Experimental Validation of Biomarkers Associated with PI3K/AKT Signaling Pathway in Spinal Cord Injury.Molecular neurobiology · 2026Article
- FGF family in health and disease.Molecular biomedicine · 2026Review
- Functional analysis of the FGF2 gene in horn development in sheep and identification of key regulatory variants.BMC genomics · 2025Article
- Myokine Levels in Relation to Bone Markers and Adipokines in Children with Prader-Willi Syndrome During Growth Hormone Therapy and Dietary Intervention.International journal of molecular sciences · 2025Article
- Sclerostin's role in bone-muscle crosstalk and osteoporosis pathogenesis.Osteoporosis and sarcopenia · 2025Review
- Hedgehog signaling directs cell differentiation and plays a critical role in tendon enthesis healing.NPJ Regenerative medicine · 2025Article
- FGF2 Functions in HMolecular biotechnology · 2024Article
- Fibroblast growth factor 2 promotes osteo/odontogenic differentiation in stem cells from the apical papilla by inhibiting PI3K/AKT pathway.Scientific reports · 2024Article
- Exploring the Role of Hormones and Cytokines in Osteoporosis Development.Biomedicines · 2024Review
- Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family.Military Medical Research · 2024Review
- Bone-organ axes: bidirectional crosstalk.Military Medical Research · 2024Review
- MicroRNA binding site variants-new potential markers of primary osteoporosis in men and women.Frontiers in genetics · 2024Article
- Nature's Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.Current medicinal chemistry · 2024Review
- Overexpression of fibroblast growth factor receptor 2 in bone marrow mesenchymal stem cells enhances osteogenesis and promotes critical cranial bone defect regeneration.Frontiers in cell and developmental biology · 2023Article
- Use of Photobiomodulation Combined with Fibrin Sealant and Bone Substitute Improving the Bone Repair of Critical Defects.Polymers · 2022Article
- Article
- Composite Coatings for Osteoblast Growth Attachment Fabricated by Matrix-Assisted Pulsed Laser Evaporation.Polymers · 2022Article
- New developments in the biology of fibroblast growth factors.WIREs mechanisms of disease · 2022Review
- Lumbar Interbody Fusion Conducted on a Porcine Model with a Bioresorbable Ceramic/Biopolymer Hybrid Implant Enriched with Hyperstable Fibroblast Growth Factor 2.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The fibroblast growth factor (FGF) regulatory axis is phylogenetically ancient, evolving into a large mammalian/human gene family of 22 ligands that bind to four receptor tyrosine kinases for a complex physiologic system controlling cell growth, differentiation, and metabolism. The tissue targets for the primary FGF function are mainly in cartilage and in bone for morphogenesis, mineralization, and metabolism. A multitude of complexities in the FGF ligand-receptor signaling pathways have made translation into therapies for FGF-related bone disorders such as osteomalacia, osteoarthritis, and osteoporosis difficult but not impossible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.